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Abstract
Background and motivation: The effectiveness of using acupuncture to treat migraine is rarely and even
suspectedly reported in the literature. In this article, we report the design and the protocol of a randomized
controlled large-scale trial to treat migraine using acupuncture, aiming at testifying it is effective to use
acupuncture to treat migraine. We demonstrate also that the effectiveness of the treatment may vary due to using
acupoints of different meridians or different acupoints of one meridian.
Methods and design: A multi-center randomized controlled trial is currently undergoing, with three acupoints
treatment groups and one non-acupoints control group. The acupuncture treatment consists of 20 sessions per
patient with a observation period of 20 weeks. In total, 480 patients with Migraine are registered in this study
within 8 hospitals in China from March 2008 to June 2009. These patients are randomly assigned to receive one
of the following four acupoints treatment groups, i.e. 1) specific acupoints of Shaoyang meridians (120 patients),
2) non-specific acupoints of Shaoyang meridians (120 patients), 3) acupoints of other meridians (120 patients); or
4) non-acupoints control group (120 patients). The main outcome measurement in this trial is the effect
comparison achieved among these four groups in terms of number of days with migraine and intensity of migraine
during and after the baseline phase, i.e. the first 4 weeks before randomization and 4, 8 and 16 weeks after
randomization. The intensity of headache including Headache intensity grade (0–3) and visual analogue scale (VAS)
score will also be used in this study. In addition, the differences of Migraine-Specific Quality-of-Life Questionnaire
(MSQ) and Transcranial Doppler Sonography (TCD) before and after randomization are also used as the
secondary outcome measurement.
Discussion: The result of this trial (which will be available in 2009) will demonstrate the efficacy of using
acupuncture to treat migraine, and verify whether the specific effect of acupoints exists and whether this specific
effect of acupoints is related to meridian and a collection of meridian Qi.
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Background
Migraine is a common disease. Population-based studies
suggest that 6% to 7% of men and 15% to 18% of women
experience migraine headache [1,2]. Acupuncture is grad-
ually accepted as a complementary or alternative medi-
cine for preventing migraine attack and relieving pain in
countries beyond China, especially in the West. Recently,
a randomized trial showed that acupuncture leads to per-
sisting, clinically relevant benefits for patients with
chronic headache, particularly migraine [3], which is con-
sistent with many results reported in the previous litera-
ture on acupuncture for headache [4-6].
However, in recent years several randomized controlled
trials argued that acupuncture was no more effective than
sham acupuncture or minimal acupuncture in reducing
migraine headache and tension-types of headache,
although it was more effective than no treatment [7,8].
Convinced evidence for the efficacy of treating migraine
with acupuncture is therefore inadequate because of these
inconsistent results. In this multi-center randomized con-
trolled large-scale trial, we firstly aim at investigating
whether acupuncture is effective to treat migraine through
a comparison with non-acupoints control. Secondly we
investigate whether its efficacy is dissimilar due to using
acupoints of different meridians or different acupoints of
one meridian. The work reported in this article is financed
by the National Basic Research Program (973 Program) in
China, and is registered with an identifier
(NCT00599586) by Clinical Trials.gov in the USA.
Methods and design
Design
This study is a multi-center randomized controlled trial
comparing three acupoints treatment groups with one
non-acupoint control group (fig. 1, fig 2). The design of
this study followed the guidelines of the HIS Committee
on Clinical Trails in Migraine [9]. The trial is completed in
the following eight hospitals: First affiliated Hospital of
Chengdu University of Traditional Chinese Medicine
(TCM); People's Hospital of Sichuan province; No.4 Peo-
ple's Hospital of Sichuan province; Affiliated Hospital of
Ningxia Medicine University; First affiliated Hospital of
Hunan University of TCM; People's Hospital of Hunan
province; No.1 People's Hospital of Wuhan City; TCM
Hospital of Wuhan City.
The total observation period within this study is 20 weeks
for each patient. All patients should have recorded head-
ache diaries for 4 weeks before randomization (baseline
phase). After randomization the patients will receive 20
sessions of 30 minutes' duration over a period of 4 weeks.
All patients are asked to document their headache diaries,
and the outcome measurement is completed both in the
baseline and 4, 8 and 16 weeks after randomization.
The patients in the acupoints treatment groups and non-
acupoint control group are blinded as to which treatment
method they received. The patients will be nevertheless
informed that they will receive either one of acupoints
treatment groups or non-acupoint control group, which
has been associated with positive outcome in clinical
studies.
The central randomization is used in this trial, which is
performed by the National Clinical Trial Center of Chi-
nese Medicine, Chengdu, Good Clinical Practice (GCP)
Center in China. The patients meeting the inclusion crite-
ria will be randomly assigned to one of acupoints treat-
ment groups or non-acupoint control group by the GCP
Center through telephone, mobile phone, mobile mes-
sage, or website, and a random number and group assign-
ment will be immediately confirmed through email. This
procedure assures that randomization will not be influ-
enced, neither by the acupuncturists nor the patients.
This trial is performed according to the principles of the
Declaration of Helsinki (Version Edinburgh 2000). And
the trial protocol has been approved by local institutional
review board and ethics committee. The written informed
consent will be requested to sign for all of participants
before registration. All patients will be given enough time
to decide whether they would sign the informed consent,
or they will be given treatment options other than acu-
puncture if they are not willing to participate.
Patients
A power analysis is calculated before conducting this trial,
which α = 0.05 and power = 90%. According to the previ-
ous literature [7], for the main outcome the number of
days with migraine, an improvement of 2.4 days by sham
acupuncture is reported. In this study, we anticipated an
improvement of 4.0 days by acupuncture, so a difference
of 1.6 days is considered minimally of clinical signifi-
cance. Therefore, the sample size in this trial can be esti-
mated initially according to the following formula [10].
Each group needs at least 120 patients (assuming a 15%
dropout rate), 480 patients in four groups totally will be
enrolled in the study.
Inclusion criteria
According to the criteria of the International Classification
of Headache Society [11], patients who meet the diagno-
sis of migraine with or without aura will include in this
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migraines for at least 1 year, with two or more migraine
attacks per month during the last three months and dur-
ing the baseline period; 2) between 18 and 65 years old
with the onset age of migraine less than 50; 3)with base-
line headache diary completed; 4) without using prophy-
lactic drugs in the previous 1 month, 5) willing to finish
20 treatments in the following 4 weeks (acupuncture
treatment period); and 6) with written consent form
signed by themselves.
Exclusion criteria
Patients with any of the following conditions will be
excluded: headache caused by organic disorders, such as
subarachnoid hemorrhage, cerebral hemorrhage, cerebral
embolism, cerebral thrombosis, vascular malformation,
arteritis, hypertension, arteriosclerosis, etc.; psychosis;
pregnant women or women in lactation; patients with
allergic constitution or easily getting infected or bleeding;
or patients having taken drugs for preventing migraine in
the last four weeks.
Interventions
It took at least twelve months to develop the treatment
strategies for this study. Interventions were according to
records in ancient books and research results of modern
papers about treating migraine with acupuncture in China
or in the West, and were formed in consensus with Chi-
nese acupuncturists and acupuncture experts, who come
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from both the study team and non-study team in all
regions where the study is being conducted. In the first
part of the clinical research of our 973 project (accom-
plished in 2007), we confirmed the location of non-acu-
points through compared one acupoints group with two
non-acupoints control groups. The final strategies for this
study are therefore defined as three acupoints treatment
groups and one non-acupoints control group.
Based on the theory of TCM and acupuncture, migraine
pertains to Shaoyang headache, and it has a close relation-
ship with Shaoyang meridians, while it dose not relate to
other meridians. Therefore, the effect of Shaoyang merid-
ian is different from that of other meridians in acupunc-
ture treatment of migraine. Additionally, in the same
meridian, the effect of specific acupoints is different from
the non-specific acupoints. Therefore, in our trial the three
acupoints treatment groups are defined as 1) treatment
Trial processes chart Figure 2
Trial processes chart. Note: VAS = visual analogue scale (0–10); MSQ = Migraine-Specific Quality-of-Life Questionnaire; 
Headache intensity grade: 0 = no headache; 1 = mild headache; 2 = moderate headache; 3 = severe headache; TCD = Tran-
scranial Doppler Sonography.
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group 1 (specific acupoints of Shaoyang meridians); 2)
treatment group 2 (non-specific acupoints of Shaoyang
meridians), and 3) treatment group 3 (acupoints of other
meridians), and one non-acupoints control group.
Treatment group 1
Waiguan (TE5), Yanglingquan (GB34), Qiuxu (GB40),
Fengchi (GB20) are punctured by filiform needles unilat-
erally. Waiguan (TE5) is punctured perpendicularly 0.5–1
cun. Yanglingquan (GB34) is punctured perpendicularly
1–1.5 cun. Qiuxu (GB40) is punctured perpendicularly
0.5–0.8 cun. Fengchi (GB20) is punctured obliquely 0.8–
1.2 cun, the tip of needle towards the tip of the nose.
Treatment group 2
Luxi (TE19), Sanyangluo (TE8), Xiyangguan (GB33),
Diwuhui (GB42) are punctured by filiform needles unilat-
erally. Luxi (TE19) is punctured transversely 0.3–0.5 cun.
Sanyangluo (TE8) is punctured perpendicularly 0.5–1
cun. Xiyangguan (GB33) is punctured perpendicularly 1–
1.5 cun. Diwuhui (GB42) is punctured perpendicularly
0.5–0.8 cun.
Treatment group 3
Touwei (ST8), Pianli (LI6), Zusanli (ST36), Chongyang
(ST42) are punctured by filiform needles unilaterally.
Touwei (ST8) is punctured transversely 0.5–1.0 cun.
Pianli (LI6) is punctured perpendicularly 0.3–0.5 cun.
Zusanli (ST36) is punctured perpendicularly 1–2 cun.
Chongyang (ST42) is punctured perpendicularly 0.3–0.5
cun, avoid needling the artery.
Control group
In the medial arm on the anterior border of the insertion
of the deltoid muscle at the junction of deltoid and biceps
muscles [12], is punctured perpendicularly 0.5–1 cun. The
edge of tibia 1 to 2 cm lateral to the Zusanli (ST36) hori-
zontally [13], is punctured perpendicularly 0.5–1 cun.
Half between the tip of the elbow and the axilla [14], is
punctured perpendicularly 0.5–1 cun. Ulnar side, half
between epicondylus medialis of the humerus and ulnar
side of the wrist [14], is punctured perpendicularly 0.5–1
cun. All non-acupoints are punctured by filiform needles
unilaterally.
In each session all acupoints and non-acupoints are punc-
tured by filiform needles unilaterally, and left and right
side are alternatively used. After 4 acupoints or non-acu-
points being needled, 4 auxiliary needles will be punc-
tured at 2 mm lateral to every acupoint or non-acupoint
and punctured to a depth of 2 mm without manual stim-
ulation. Transcutaneous electric acupoint stimulation
(HANS: Han's acupoint nerve stimulator, HANS-200,
made in Nanjing, China) is used for electro-acupuncture
stimulation at every acupoint or non-acupoint after nee-
dle insertion. Each acupuncture needle of acupoints or
non-acupoints and its auxiliary needle are connected with
the electricity by HANS for 30 minutes. The stimulation
frequency is 2/100 Hz. The stimulation intensity varied
from 0.1 mA to 1.0 mA until the patients feel comfortable.
The filiform needles are used in this trial, which are sterile
acupuncture needles for single use; namely Hwato Nee-
dles, made in Suzhou, China, 25–40 mm in length and
0.25 mm in diameter. The needles with 13 mm in length
and 0.18 mm in diameter especially are used as auxiliary
needle without manipulating the needles. The acupoints
of the treatment groups are asked to achieve DeQi sensa-
tion by lifting and thrusting combined with twirling and
rotating the needles, but the non-acupoints of control
group are not asked to achieve DeQi sensation by the
same manipulating the needles. Both the treatment
groups and control group are asked to retain the needles
for 30 minutes, and close the acupoint holes with clean
cotton balls to avoid bleeding when withdrawing the nee-
dle.
All patients will receive 20 treatments totally over a period
of 4 weeks, once a day, five times continuously and two
days interval in a week.
Outcome measurement
The main outcome measures in the trial are the differences
between the number of days with migraine and intensity
of headache in the headache diaries during 4 weeks before
randomization and 4, 8, and 16 weeks after randomiza-
tion. The intensity of headache includes the Headache
intensity grade (0–3) and visual analogue scale (VAS)
score (0–10). The secondary Outcome Measures are the
differences in frequency of migraine attacks (episodes of
migraine headaches separated by pain free intervals of at
least 48 hours), average duration of a migraine attack, rate
of rescue medication used, number of patients with
adverse side effects, Migraine-Specific Quality-of-Life
Questionnaire (MSQ) before randomization and 4, 8, and
16 weeks after randomization, and the differences in Tran-
scranial Doppler Sonography (TCD) before randomiza-
tion and 4 weeks after randomization.
All patients fill in headache diaries during 4 weeks before
randomization (baseline phase) and 4, 8, and 16 weeks
after randomization. In the diaries they document the
time of attack and stopping of headache, the intensity, the
frequency, the location and the cause of headache, associ-
ated symptoms in each migraine attack. The patients doc-
ument whether or not they take the medicine during
treatment periods, and if patients take medicine they have
to document the name, dosage of the medicine, the time
of taking medicine, the time of relieving pain and the side
effect of the medicine. In addition, all patients will acceptTrials 2008, 9:57 http://www.trialsjournal.com/content/9/1/57
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routine test of blood, urine and stool, and electrocardio-
gram (ECG), liver function (ALT, AST), kidney function
(BUN, Scr) before randomization, in order to exclude
these patients who have serious illness in heart, liver and
kidney or other severe disease.
Any adverse events, and how they are addressed, are
recorded during the four treatment weeks and twelve fol-
low-up weeks. These adverse events include bleeding,
hematoma, fainting, serious pain, and local infection. If
patients suffer any serious adverse events, all details will
be documented.
All acupuncturists are required to attend special training
classes in order to understand the details of this trial. The
special training classes have theoretical lessons and prac-
tical lessons. All people have to understand the purpose
and content of the trial, treatment strategies and quality
control. For instance, they are trained to know how to use
the central randomization method, how to fill in the CRF
(case report form) and electro-CRF, how to locate the
points and manipulate the needles, etc. The acupunctur-
ists must take part in all of the training classes as well and
have to pass the special training test before they are qual-
ified to perform this trial. Additionally, in order to keep
quality control, a special quality examination form is
made for checking the whole processes of the trial and
documenting the details of the processes. This work is per-
formed by the special trained checkers once a month in
every hospital in the centers.
Drop-outs or withdrawals and their reasons, and patient's
compliance have to be documented during the four treat-
ment weeks and twelve follow-up weeks. All patients are
recorded until the end of the trial.
Statistical analysis
Analysis of all data in this trial will be performed by the
National Clinical Trial Center of Chinese Medicine
(Chengdu GCP Center) in China, which is performed in a
blinded manner because analysis of data is done by a spe-
cial analysis-researcher. The data will be analyzed with
SPSS13.0 and SAS9.0 statistical software packages.
The intention-to-treat (ITT) population is defined as the
patients who are randomized. The data analysis of base-
line characteristics is based on the intention-to-treat (ITT)
population. And the data analysis of the primary and sec-
ondary outcomes and other outcomes is mainly based on
the intention-to-treat (ITT) population. In addition the
per-protocol (PP) population is analyzed. The result of
the ITT analysis will be compared with that of the PP anal-
ysis to check whether the results are consistent.
The first step of analysis is to make comparisons among
baseline characteristics in different groups. The second
step is to check whether acupoints treatment groups were
more efficacious in treating migraine than non-acupoints
control group. If acupoints treatment is more effective
than non-acupoints treatment in treating migraine, the
third step is to make comparisons among three acupoints
treatment groups in effectiveness of treating migraine.
For normal distribution data (normality, homogeneity of
variances) the repeated measures analysis will be used in
the different time-points assessment. The Kruskal-Wallis
test will be employed in the analysis of skewed distribu-
tion data. Moreover, analysis of variance (ANOVA) and
used for numerical variables, Chi-square test is used for
categorical variables. Two-sided test is applied for all
available data, and a P value < 0.05 is considered statisti-
cally significant.
Discussions
The National Basic Research Program (973 Program) is
the most important basic research program based on clin-
ical practice in China. Our project is the largest clinical
trial involved in the specific physiological effects of acu-
points, financially supported by the 973 Program. Because
of a controversial issue reported in other studies about the
specific effect of acupoints, our project aims to clarify this
issue by means of a multi-center randomized controlled
trial.
The study reported in this article is the second part of our
973 project. It involves in comparing the efficacy of acu-
points treatment with non-acupoints treatment and the
efficacy of different acupoints treatment, after efficacy of
acupuncture treating migraine is convinced from the first
part of our project.
According to the theory of TCM and acupuncture, there is
no doubt that the differences between acupoints and non-
acupoints in specific physiological effects do exist. Acu-
puncture has also been recognized as a method for treat-
ing many diseases, not only widely in China due to its
long history in clinical practice, but also gradually in
many western countries due to its increasing popularity.
However, in recent years diverse observations about 'spe-
cific' and 'unspecific' effects of acupoints have also been
experienced by a few clinical trials in the West. For
instance, a randomized controlled trial illustrated from
their study that acupuncture was no more effective than
sham acupuncture or minimal acupuncture in reducing
migraine headache and tension-types of headache,
despite its effectiveness compared with no treatment
[7,8]. Their results suspected that acupuncture effect may
be due to unspecific physiology effects of needling, to a
powerful placebo effect, or to a combination of both [7].Trials 2008, 9:57 http://www.trialsjournal.com/content/9/1/57
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We argue, however, through our early investigation and
the undergoing multi-center randomized controlled large-
scale trial, that acupuncture does have effect in treating
migraine. Through the reported studies in this article, we
examine the efficacy of acupuncture for treating migraine
to large samples of patients. Furthermore, we investigate
whether the different efficacy of three acupoints treatment
groups is due to the acupoints of different meridians or
different acupoints of one meridian. We believe this trial
could demonstrate that the efficacy of using acupuncture
to treat migraine is not due to physiological effects of acu-
points suspected in [7], but the real 'specific effects' of acu-
points based on meridians and a collection of meridian
Qi.
Central randomization is used in our trial, which is a
strict, complete randomization, and ensures adequate
concealment. During the whole trial period, the patients
are not aware of which group they belong to, but they do
know they will receive acupuncture needling treatments
by either puncturing different acupoints or puncturing
non-acupoints.
Before the trial started, we spent plenty of time to define
the non-acupoints control groups because the location of
non-acupoints were used differently compared to the pre-
vious literature in China and in the West. In most Chinese
literature, the location of the non-acupoints used was
selected beside the therapeutic acupoints and half
between the two lines or two acupoints [15,16], while a
few other reports in Western literature recorded the loca-
tion of non-acupoints differently [12,17]. In our previous
trials, two control groups from a consensus of acupunc-
ture experts have been studied. So, the non-acupoints con-
trol group was defined finally according to the first part of
our 973 project.
In a word, the purpose of this trial is to provide convinced
evidence that specific effect of acupoints for treating
migraine does not only exist but also differs according to
the meridian and the collection of meridian Qi used.
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